Literature DB >> 12180305

Consensus conference. Treatment of hepatitis C.

.   

Abstract

This conference was organized according to the methodological rules published by the Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES). The conclusions and recommendations contained in this document were written, in full independence, by the jury of the conference. ANAES is in no way accountable for these views.

Mesh：

Substances：

Year:  2002        PMID： 12180305

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN： 0399-8320


  10 in total

1.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

2.  Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.

Authors:  A Pivert; C Payan; P Morand; S Fafi-Kremer; J Deshayes; F Carrat; S Pol; P Cacoub; C Perronne; F Lunel
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

3.  Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection.

Authors:  J Ghosn; C Deveau; C Goujard; I Garrigue; N Saïchi; J Galimand; Z Nagy; C Rouzioux; L Meyer; M-L Chaix
Journal:  Sex Transm Infect       Date:  2006-08-21       Impact factor: 3.519

4.  Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage.

Authors:  Romain Moirand; Marc Bilodeau; Suzanne Brissette; Julie Bruneau
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

5.  Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C.

Authors:  Moana Gelu-Simeon; Aurore Burlaud; Jacques Young; Gilles Pelletier; Catherine Buffet
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

6.  Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study.

Authors:  Patrice Cacoub; Denis Ouzan; Pascal Melin; Jean-Philippe Lang; Michel Rotily; Thierry Fontanges; Marina Varastet; Michel Chousterman; Patrick Marcellin
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

7.  10-year trends in the diagnosis and treatment of hepatitis C and concomitant mental health disorders: 1995 to 2005.

Authors:  Barbara P Yawn; Liliana Gazzuola Rocca; Peter C Wollan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 8.  Immunological HCV-associated thrombocytopenia: short review.

Authors:  Dimitrios Dimitroulis; Serena Valsami; Paraskevas Stamopoulos; Gregory Kouraklis
Journal:  Clin Dev Immunol       Date:  2012-07-10

9.  Treatment of acute hepatitis C virus infection with interferon-alpha 2b and ribavirin: case report and review of the literature.

Authors:  Hakan Leblebicioglu; Derya Bayirli; Saban Esen; Mustafa Sunbul; Cafer Eroglu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2002-10-14       Impact factor: 3.944

10.  High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002.

Authors:  Cécile Henquell; Carole Cartau; Armand Abergel; Henri Laurichesse; Christel Regagnon; Christophe De Champs; Jean-Luc Bailly; Hélène Peigue-Lafeuille
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.